Keyphrases
Medicare Advantage
100%
Cancer Treatment
100%
Traditional Medicare
100%
Insurer
25%
Ovarian Cancer
16%
Breast Cancer
16%
Castration-resistant Prostate Cancer
16%
Lung Cancer
16%
Bevacizumab
16%
Chemotherapy
16%
Paclitaxel
16%
Nab-paclitaxel
16%
Granulocyte Colony-stimulating Factor (G-CSF)
16%
Low Risk
16%
Denosumab
16%
Generic Drugs
16%
Biosimilar
16%
Medicare
8%
Carboplatin
8%
Medicare Population
8%
Medicare Data
8%
Effective Strategies
8%
Retrospective Analysis
8%
Cancer Drugs
8%
Cancer Diagnosis
8%
Limited Information
8%
Low Utilization
8%
Utilization Rate
8%
Low Use
8%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Paclitaxel
44%
Chemotherapy
22%
Prostate Cancer
22%
Ovary Cancer
22%
Lung Cancer
22%
Breast Cancer
22%
Bevacizumab
22%
Biological Product
22%
Granulocyte Colony Stimulating Factor
22%
Biosimilar Agent
22%
Denosumab
22%
Carboplatin
11%
Medicine and Dentistry
Cancer Therapy
100%
Medicare
100%
Paclitaxel
17%
Biological Product
8%
Prostate Cancer
8%
Breast Cancer
8%
Lung Cancer
8%
Ovarian Cancer
8%
Granulocyte Colony Stimulating Factor
8%
Biosimilar
8%
Denosumab
8%
Bevacizumab
8%
Carboplatin
4%
Cancer Diagnosis
4%
Cancer Treatment
4%
Agricultural and Biological Sciences
Malignant Neoplasm
100%
Paclitaxel
33%
Granulocyte Colony-Stimulating Factor
16%
Bevacizumab
16%
Lung
16%
Denosumab
16%
Ovary Cancer
16%
Ovarian Cancer
16%